Virus engineered to fight cancer shows promise in early trial
Disease control
Completed
This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC